leucylleucine (Leu-Leu)

RN given refers to (DL-Leu-DL-Leu)-isomer

Also Known As:

Leu-Leu; L-leucyl-L-leucine; leucyl-leucine; leucylleucine monohydrochloride, (L-Leu-L-Leu)-isomer; leucylleucine, (D-Leu-D-Leu)-isomer; leucylleucine, (L-Leu-D-Leu)-isomer; leucylleucine, (L-Leu-L-Leu)-isomer

Networked: 106 relevant articles (3 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - leucylleucine: 106

Experts

1.	Shimizu, Kenji: 2 articles (01/2016 - 02/2005)
2.	Oulie, Inger: 2 articles (11/2007 - 01/2006)
3.	Skotland, Tore: 2 articles (11/2007 - 01/2006)
4.	Bracher, Lisamaria: 1 article (01/2022)
5.	Candinas, Daniel: 1 article (01/2022)
6.	Ferro, Iolanda: 1 article (01/2022)
7.	Gallo, Stefano: 1 article (01/2022)
8.	Ganapathy, Ashwinkumar Subramenium: 1 article (01/2022)
9.	Gavini, Jacopo: 1 article (01/2022)
10.	Koltun, Walter: 1 article (01/2022)

Related Diseases

1.	Atherosclerosis 01/01/2023 - "The current study investigated the therapeutic effects of inhibition of GSDMD activation by the novel GSDMD inhibitor N-Benzyloxycarbonyl-Leu-Leu-Ser-Asp(OMe)-fluoromethylketone (Z-LLSD-FMK), the specific caspase-1 inhibitor N-Benzyloxycarbonyl-Tyr-Val-Ala-Asp(OMe)-fluoromethylketone (Z-YVAD-FMK), and a combination of both on atherosclerosis in ApoE-/- mice fed a western diet at 5 weeks of age, and further determined the efficacy of these polypeptide inhibitors in bone marrow-derived macrophages (BMDMs). "
2.	Tics (Tic) 11/01/2009 - "Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. "
3.	Hallucinations (Hallucination) 09/01/2008 - "In addition, patients who were phe carriers (N=144) had significantly greater severity of positive symptoms (hallucinations) compared to patients who were leu/leu homozygotes (N=56). "
4.	Glioblastoma (Glioblastoma Multiforme) 11/01/2009 - "Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. "
5.	Prostatic Neoplasms (Prostate Cancer) 06/01/2011 - "Our results suggest that the HPC/ELAC-2 polymorphisms, especially in localized cases, could help to predict prostate cancer risk and confirm its high prevalence of the leu/leu allele in north Indian population. " 02/04/2013 - "A competitive inhibition study revealed that peptide transporters in prostate cancer cells exhibited broad substrate specificity with a preference for hydrophobic dipeptides, such as Leu-Leu. " 07/01/2012 - "Overall, no significant association was found between the CYP1B1 Leu432Val polymorphism and prostate cancer susceptibility for Val/Val vs Leu/Leu (OR = 1.07; 95% CI: 0.79-1.44; P = 0.67), Leu/Val vs Leu/Leu (OR = 1.05; 95% CI: 0.94-1.17; P = 0.42), Leu/Val + Val/Val vs Leu/Leu (OR = 1.07; 95% CI: 0.91-1.26; P = 0.40) and Val/Val vs Leu/Val + Leu/Leu (OR = 1.11; 95% CI: 0.86-1.44; P = 0.43). " 09/01/2006 - "The decreased risk we observed with the hOGG1 326 Cys/Cys genotype confirms an earlier report and the further reduced risk found with the CYP1B1 (432 Leu/Leu or Leu/Val)-hOGG1 (326 Cys/Cys)-XRCC1 (Arg/Arg or Arg/Gln) genotype combination may lend new insights to the importance of ROS generated from non-receptor-mediated estrogenic mechanisms in more aggressive prostate cancer."

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	alanylaspartic acid
3.	Therapeutic Uses
4.	Apolipoproteins E (ApoE)
5.	benzyloxycarbonyltyrosyl- valyl- alanyl- aspartic acid fluoromethyl ketone
6.	interleukin-1beta-converting enzyme inhibitor
7.	Esters
8.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
9.	valylvaline (Val-Val)
10.	valylleucine

Related Therapies and Procedures

1.	Catheters
2.	Intranasal Administration